22 May 2013
Keywords: Merck & Co, Lycera, Immune-mediated disorders
Article | 13 February 2013
USA-based drug developer Lycera Corp has announced a new agreement with US pharma giant Merck & CO (NYSE: MRK) - ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 February 2013
21 May 2013
© 2013 thepharmaletter.com